| pubmed-article:9154964 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9154964 | lifeskim:mentions | umls-concept:C0070829 | lld:lifeskim |
| pubmed-article:9154964 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:9154964 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:9154964 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:9154964 | lifeskim:mentions | umls-concept:C0260181 | lld:lifeskim |
| pubmed-article:9154964 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:9154964 | pubmed:dateCreated | 1997-6-6 | lld:pubmed |
| pubmed-article:9154964 | pubmed:abstractText | A series of 6-aryl-4,5-heterocyclic-fused pyridazinones were designed and synthesized as selective phosphodiesterase (PDE) IV inhibitors. Biological evaluation of these compounds demonstrated a good selectivity profile toward the PDE IV family and greatly attenuated affinity for the Rolipram high-affinity binding site that seems to be responsible for undesiderable side effects. Structure-activity relationships (SARs) studies showed that the presence of an ethyl group at pyridazine N-2 is associated with the best potency and selectivity profile. | lld:pubmed |
| pubmed-article:9154964 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9154964 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9154964 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9154964 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9154964 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9154964 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9154964 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9154964 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9154964 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9154964 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9154964 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9154964 | pubmed:month | May | lld:pubmed |
| pubmed-article:9154964 | pubmed:issn | 0022-2623 | lld:pubmed |
| pubmed-article:9154964 | pubmed:author | pubmed-author:PalaciosJ MJM | lld:pubmed |
| pubmed-article:9154964 | pubmed:author | pubmed-author:SegarraVV | lld:pubmed |
| pubmed-article:9154964 | pubmed:author | pubmed-author:Dal PiazVV | lld:pubmed |
| pubmed-article:9154964 | pubmed:author | pubmed-author:BeletaJJ | lld:pubmed |
| pubmed-article:9154964 | pubmed:author | pubmed-author:DoménechTT | lld:pubmed |
| pubmed-article:9154964 | pubmed:author | pubmed-author:GiovannoniM... | lld:pubmed |
| pubmed-article:9154964 | pubmed:author | pubmed-author:CastellanaCC | lld:pubmed |
| pubmed-article:9154964 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9154964 | pubmed:day | 9 | lld:pubmed |
| pubmed-article:9154964 | pubmed:volume | 40 | lld:pubmed |
| pubmed-article:9154964 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9154964 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9154964 | pubmed:pagination | 1417-21 | lld:pubmed |
| pubmed-article:9154964 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:9154964 | pubmed:meshHeading | pubmed-meshheading:9154964-... | lld:pubmed |
| pubmed-article:9154964 | pubmed:meshHeading | pubmed-meshheading:9154964-... | lld:pubmed |
| pubmed-article:9154964 | pubmed:meshHeading | pubmed-meshheading:9154964-... | lld:pubmed |
| pubmed-article:9154964 | pubmed:meshHeading | pubmed-meshheading:9154964-... | lld:pubmed |
| pubmed-article:9154964 | pubmed:meshHeading | pubmed-meshheading:9154964-... | lld:pubmed |
| pubmed-article:9154964 | pubmed:meshHeading | pubmed-meshheading:9154964-... | lld:pubmed |
| pubmed-article:9154964 | pubmed:meshHeading | pubmed-meshheading:9154964-... | lld:pubmed |
| pubmed-article:9154964 | pubmed:meshHeading | pubmed-meshheading:9154964-... | lld:pubmed |
| pubmed-article:9154964 | pubmed:meshHeading | pubmed-meshheading:9154964-... | lld:pubmed |
| pubmed-article:9154964 | pubmed:meshHeading | pubmed-meshheading:9154964-... | lld:pubmed |
| pubmed-article:9154964 | pubmed:meshHeading | pubmed-meshheading:9154964-... | lld:pubmed |
| pubmed-article:9154964 | pubmed:meshHeading | pubmed-meshheading:9154964-... | lld:pubmed |
| pubmed-article:9154964 | pubmed:meshHeading | pubmed-meshheading:9154964-... | lld:pubmed |
| pubmed-article:9154964 | pubmed:meshHeading | pubmed-meshheading:9154964-... | lld:pubmed |
| pubmed-article:9154964 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9154964 | pubmed:articleTitle | Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors. | lld:pubmed |
| pubmed-article:9154964 | pubmed:affiliation | Dipartimento di Scienze Farmaceutiche, Firenze, Italy. | lld:pubmed |
| pubmed-article:9154964 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9154964 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:9154964 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9154964 | lld:pubmed |
